Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Laurie Gaspar

Concepts (490)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Brain Neoplasms
101
2025
1325
5.910
Why?
Lung Neoplasms
93
2026
2675
4.920
Why?
Carcinoma, Non-Small-Cell Lung
54
2022
1195
3.780
Why?
Radiosurgery
44
2022
398
3.570
Why?
Small Cell Lung Carcinoma
13
2026
125
2.770
Why?
Cranial Irradiation
21
2025
85
2.750
Why?
Radiotherapy, Intensity-Modulated
10
2026
143
1.170
Why?
Combined Modality Therapy
62
2022
1271
1.170
Why?
Radiation Pneumonitis
5
2021
31
1.140
Why?
Carcinoma, Small Cell
8
2007
172
1.060
Why?
Antineoplastic Combined Chemotherapy Protocols
31
2026
1998
1.030
Why?
Radiotherapy Dosage
40
2026
289
1.030
Why?
Neoplasm Staging
39
2020
1488
1.000
Why?
Chemoradiotherapy
8
2020
238
0.940
Why?
Practice Guidelines as Topic
11
2021
1591
0.920
Why?
Brachytherapy
12
2017
132
0.860
Why?
Radiotherapy Planning, Computer-Assisted
11
2021
150
0.830
Why?
Radiation Oncology
12
2022
83
0.800
Why?
Glioblastoma
18
2016
350
0.800
Why?
Neoplasm Recurrence, Local
21
2017
1160
0.780
Why?
Radiotherapy, Conformal
9
2026
75
0.680
Why?
Adenocarcinoma
13
2022
927
0.670
Why?
Glioma
15
2015
425
0.670
Why?
Aged
104
2026
26432
0.650
Why?
Liver Neoplasms
8
2009
776
0.640
Why?
Survival Rate
31
2018
2092
0.630
Why?
Esophageal Neoplasms
9
2008
351
0.630
Why?
Humans
223
2026
146342
0.630
Why?
Prognosis
45
2022
4351
0.630
Why?
Middle Aged
120
2026
36619
0.600
Why?
Radiotherapy
14
2017
209
0.600
Why?
Radiotherapy, Adjuvant
16
2022
222
0.590
Why?
Clinical Trials as Topic
18
2018
1064
0.590
Why?
Neurosurgeons
1
2019
17
0.580
Why?
Evidence-Based Medicine
10
2021
731
0.570
Why?
Dacarbazine
9
2016
98
0.570
Why?
Four-Dimensional Computed Tomography
6
2021
38
0.550
Why?
Cisplatin
19
2026
347
0.520
Why?
Oncologists
1
2018
47
0.510
Why?
Re-Irradiation
3
2026
10
0.500
Why?
Carcinoma, Squamous Cell
10
2017
628
0.500
Why?
Patient Selection
10
2019
728
0.490
Why?
Male
130
2026
73396
0.480
Why?
Clinical Decision-Making
3
2021
365
0.470
Why?
Aged, 80 and over
45
2020
8391
0.460
Why?
Physician's Role
1
2018
225
0.460
Why?
Female
133
2026
79499
0.460
Why?
Antineoplastic Agents, Alkylating
8
2016
76
0.460
Why?
Antineoplastic Agents
20
2017
2219
0.450
Why?
Induction Chemotherapy
2
2013
87
0.420
Why?
Receptor Protein-Tyrosine Kinases
5
2017
227
0.400
Why?
Adult
91
2025
41087
0.400
Why?
Survival Analysis
24
2020
1378
0.390
Why?
Treatment Outcome
37
2026
11821
0.390
Why?
Physician-Patient Relations
1
2018
597
0.370
Why?
Etoposide
12
2021
169
0.370
Why?
Pro-Opiomelanocortin
7
1989
20
0.350
Why?
Pneumonectomy
2
2015
169
0.330
Why?
Astrocytoma
9
2014
128
0.330
Why?
Retrospective Studies
40
2022
17438
0.310
Why?
Melanoma
5
2018
765
0.300
Why?
Societies, Medical
7
2021
907
0.300
Why?
Pulmonary Ventilation
4
2021
80
0.300
Why?
Whole-Body Irradiation
1
2009
73
0.300
Why?
Guidelines as Topic
2
2020
267
0.290
Why?
Protein Kinase Inhibitors
4
2021
983
0.290
Why?
Chemotherapy, Adjuvant
12
2017
429
0.290
Why?
Karnofsky Performance Status
11
2020
37
0.290
Why?
ErbB Receptors
8
2022
636
0.290
Why?
Guideline Adherence
4
2018
594
0.280
Why?
Medical Oncology
7
2021
345
0.280
Why?
Quinazolines
6
2014
267
0.280
Why?
Dose-Response Relationship, Radiation
11
2019
141
0.270
Why?
Iodine Radioisotopes
6
2006
139
0.270
Why?
Lung
9
2021
4122
0.270
Why?
Controlled Clinical Trials as Topic
1
2007
26
0.260
Why?
Breast Neoplasms
9
2020
2418
0.260
Why?
Neoplasm Metastasis
8
2019
693
0.260
Why?
Radiopharmaceuticals
5
2014
210
0.260
Why?
Disease Progression
13
2018
2867
0.250
Why?
Follow-Up Studies
22
2018
5439
0.250
Why?
Prospective Studies
23
2026
8123
0.240
Why?
Tumor Burden
9
2017
326
0.240
Why?
Anticonvulsants
2
2019
253
0.240
Why?
Biomarkers, Tumor
6
2021
1339
0.230
Why?
Paclitaxel
5
2011
260
0.230
Why?
Proto-Oncogene Proteins B-raf
2
2017
231
0.220
Why?
Tomography, X-Ray Computed
10
2018
2786
0.220
Why?
Spinal Cord
4
2018
378
0.210
Why?
Steroids
2
2019
160
0.210
Why?
Taxoids
5
2015
115
0.200
Why?
Carcinoma
1
2006
225
0.200
Why?
Lymphatic Metastasis
3
2017
335
0.200
Why?
Central Nervous System
2
2017
278
0.200
Why?
Gastrointestinal Neoplasms
3
2019
74
0.190
Why?
Carcinoma, Renal Cell
3
2018
231
0.190
Why?
Carcinoma, Hepatocellular
2
2005
370
0.190
Why?
Magnetic Resonance Imaging
9
2019
3926
0.190
Why?
Radiography
8
2014
861
0.180
Why?
Necrosis
3
2019
243
0.180
Why?
Medical Illustration
2
2012
10
0.170
Why?
Organs at Risk
2
2012
37
0.170
Why?
Randomized Controlled Trials as Topic
7
2021
1763
0.170
Why?
Ribs
2
2012
35
0.170
Why?
Positron Emission Tomography Computed Tomography
2
2020
122
0.170
Why?
Brachial Plexus
2
2012
34
0.170
Why?
Professional Staff Committees
4
2001
11
0.170
Why?
Oligodendroglioma
4
2014
15
0.160
Why?
Esophagectomy
1
2002
136
0.160
Why?
Testicular Neoplasms
1
2022
108
0.160
Why?
Neoplasms
6
2020
2954
0.160
Why?
Mutation
4
2021
4093
0.160
Why?
Peptide Fragments
4
1989
693
0.150
Why?
Research Design
7
2018
1143
0.150
Why?
Proportional Hazards Models
8
2020
1331
0.150
Why?
Metalloporphyrins
3
2011
62
0.150
Why?
Thymus Neoplasms
2
2017
30
0.150
Why?
Thymoma
2
2017
38
0.150
Why?
Hippocampus
1
2025
989
0.150
Why?
Consolidation Chemotherapy
1
2019
11
0.150
Why?
Esophagus
2
2012
260
0.150
Why?
Meningeal Neoplasms
3
2017
95
0.140
Why?
Maximum Tolerated Dose
6
2010
217
0.140
Why?
Time Factors
10
2019
7109
0.140
Why?
Congresses as Topic
2
2019
226
0.140
Why?
Quality of Life
6
2025
3200
0.140
Why?
Radiation Injuries
5
2015
149
0.140
Why?
Expert Testimony
1
2019
43
0.140
Why?
Watchful Waiting
1
2019
90
0.140
Why?
Aquaporin 4
1
2019
101
0.140
Why?
Gray Matter
1
2019
96
0.130
Why?
Intracranial Arteriovenous Malformations
2
1995
53
0.130
Why?
Spinal Neoplasms
1
2018
36
0.130
Why?
CTLA-4 Antigen
1
2018
105
0.130
Why?
Intersectoral Collaboration
1
2018
64
0.130
Why?
Carboplatin
4
2011
168
0.130
Why?
Endpoint Determination
1
2018
84
0.130
Why?
Treatment Failure
5
2014
361
0.130
Why?
Professional Competence
1
2018
90
0.130
Why?
Kidney Neoplasms
3
2018
419
0.130
Why?
Genes, ras
1
2017
70
0.130
Why?
Cognition
4
2013
1292
0.120
Why?
Decision Trees
1
1997
76
0.120
Why?
Triazines
2
2009
48
0.120
Why?
Pituitary Neoplasms
5
1994
190
0.120
Why?
Proto-Oncogene Proteins c-kit
1
2017
73
0.120
Why?
Antineoplastic Agents, Immunological
1
2019
200
0.120
Why?
Interdisciplinary Communication
1
2018
200
0.120
Why?
Mortality
1
2019
375
0.120
Why?
Hemangioma, Cavernous
2
1993
11
0.120
Why?
Fluorouracil
6
2004
231
0.120
Why?
Brain
5
2019
2991
0.120
Why?
Salvage Therapy
4
2017
166
0.120
Why?
Programmed Cell Death 1 Receptor
1
2018
268
0.120
Why?
Pulmonary Atelectasis
1
2015
15
0.120
Why?
Antibodies
1
2018
400
0.120
Why?
Cohort Studies
7
2019
6077
0.110
Why?
Age Factors
8
2017
3347
0.110
Why?
Adrenal Cortex Hormones
1
2019
486
0.110
Why?
Accreditation
2
2013
100
0.110
Why?
Patient Preference
1
2018
226
0.110
Why?
Radiation-Sensitizing Agents
5
2009
43
0.110
Why?
Antineoplastic Agents, Phytogenic
2
2006
178
0.110
Why?
Medically Underserved Area
1
2016
102
0.110
Why?
Radiographic Image Interpretation, Computer-Assisted
1
2015
121
0.110
Why?
Postoperative Care
1
2017
301
0.110
Why?
United States
13
2022
16136
0.100
Why?
Central Nervous System Neoplasms
1
2017
177
0.100
Why?
Receptors, Progesterone
4
2020
242
0.100
Why?
Carmustine
7
2010
52
0.100
Why?
Analysis of Variance
5
2014
1298
0.100
Why?
Perfusion Imaging
1
2014
66
0.100
Why?
Fibrosarcoma
1
1993
22
0.100
Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
23
0.100
Why?
Camptothecin
2
2011
139
0.100
Why?
Risk Assessment
3
2021
3712
0.100
Why?
Triple Negative Breast Neoplasms
1
2017
220
0.100
Why?
Cerebellar Neoplasms
2
1996
169
0.100
Why?
Contraindications
2
2008
88
0.100
Why?
Nelson Syndrome
4
1987
5
0.100
Why?
Medulloblastoma
2
1996
208
0.100
Why?
Adolescent
22
2017
22557
0.090
Why?
Respiratory Function Tests
1
2015
543
0.090
Why?
Kaplan-Meier Estimate
5
2019
970
0.090
Why?
Disease-Free Survival
6
2014
778
0.090
Why?
Gene Expression Regulation, Neoplastic
1
2019
1432
0.090
Why?
Pyrazoles
2
2014
517
0.090
Why?
beta-Endorphin
3
1989
4
0.090
Why?
Pyridines
2
2014
610
0.090
Why?
Radiotherapy, High-Energy
4
2000
17
0.090
Why?
Particle Accelerators
1
1991
9
0.090
Why?
Adrenocorticotropic Hormone
3
1989
145
0.090
Why?
Pancreatic Neoplasms
1
2000
944
0.080
Why?
Forced Expiratory Volume
2
2015
451
0.080
Why?
Bone Neoplasms
3
2007
272
0.080
Why?
Radiation Protection
2
2009
41
0.080
Why?
Quality Assurance, Health Care
3
2009
349
0.080
Why?
Hyperthermia, Induced
1
1992
119
0.080
Why?
Young Adult
8
2017
14330
0.080
Why?
Technology, Radiologic
1
2010
6
0.080
Why?
Radiotherapy, Computer-Assisted
1
2010
12
0.080
Why?
Bevacizumab
3
2015
169
0.080
Why?
MEDLINE
1
2009
20
0.080
Why?
Databases, Factual
5
2017
1493
0.080
Why?
Spine
1
1991
184
0.080
Why?
Clinical Trials, Phase II as Topic
2
2002
74
0.080
Why?
Multivariate Analysis
6
2020
1543
0.070
Why?
Neurosurgery
1
2009
39
0.070
Why?
Adenoma
4
1994
210
0.070
Why?
Severity of Illness Index
2
2008
2921
0.070
Why?
Adrenal Medulla
1
1989
10
0.070
Why?
Neurotensin
1
1989
14
0.070
Why?
Drug Therapy
1
2009
85
0.070
Why?
Fractures, Spontaneous
1
1988
15
0.070
Why?
Piperidines
1
2010
225
0.070
Why?
Risk Factors
7
2021
10921
0.070
Why?
Meta-Analysis as Topic
1
2009
173
0.070
Why?
Ependymoma
2
2009
177
0.070
Why?
Catheter Ablation
1
2012
355
0.070
Why?
Esophageal Fistula
2
2000
20
0.070
Why?
Equipment Failure Analysis
1
2009
124
0.070
Why?
Imaging, Three-Dimensional
2
2010
582
0.070
Why?
Liver
2
2008
1864
0.070
Why?
Humeral Fractures
1
1988
48
0.070
Why?
Pheochromocytoma
1
1989
67
0.070
Why?
Radionuclide Imaging
1
2008
116
0.070
Why?
Education, Medical, Graduate
1
2013
568
0.070
Why?
Respiratory Mechanics
1
2008
74
0.070
Why?
Lymph Node Excision
1
2009
174
0.070
Why?
Adrenal Gland Neoplasms
1
1989
99
0.070
Why?
Femoral Fractures
1
1988
86
0.070
Why?
Craniopharyngioma
1
2009
77
0.070
Why?
Positron-Emission Tomography
2
2008
343
0.070
Why?
Chromatography, Gel
4
1989
131
0.070
Why?
Surveys and Questionnaires
2
2018
6073
0.060
Why?
Pulmonary Disease, Chronic Obstructive
1
2015
928
0.060
Why?
Palliative Care
5
2018
1032
0.060
Why?
Kidney
2
2005
1498
0.060
Why?
Statistics, Nonparametric
2
2018
426
0.060
Why?
Radioimmunoassay
4
1989
162
0.060
Why?
Vascular Diseases
1
2009
252
0.060
Why?
Genetic Markers
2
2017
340
0.060
Why?
Whole Body Imaging
1
2006
29
0.060
Why?
Uterine Cervical Neoplasms
1
1989
269
0.060
Why?
Hepatitis B, Chronic
1
2005
22
0.060
Why?
Neoplasm Grading
2
2020
313
0.060
Why?
Biomedical Research
2
2009
729
0.060
Why?
Linear Models
3
2017
857
0.060
Why?
Drug Administration Schedule
3
2014
790
0.060
Why?
Vascular Endothelial Growth Factor A
1
2008
545
0.060
Why?
Strontium Radioisotopes
2
2006
3
0.060
Why?
Seizures
1
2009
489
0.060
Why?
Diagnostic Imaging
3
2009
340
0.050
Why?
Databases as Topic
1
2005
70
0.050
Why?
Gene Rearrangement
2
2018
156
0.050
Why?
Consensus
2
2021
467
0.050
Why?
Delivery of Health Care
1
2012
947
0.050
Why?
Antiemetics
1
2005
51
0.050
Why?
Hemoglobins
1
2007
384
0.050
Why?
Clinical Competence
1
2013
1272
0.050
Why?
Pituitary Hormones
1
1984
15
0.050
Why?
Peptides
3
1985
992
0.050
Why?
Organ Size
1
2005
465
0.050
Why?
Immunotherapy
2
2022
671
0.050
Why?
Body Fluids
1
1985
70
0.050
Why?
Physicians
1
2013
955
0.050
Why?
Retreatment
3
2012
79
0.050
Why?
Age Distribution
1
2005
399
0.050
Why?
Dexamethasone
3
2012
368
0.050
Why?
Cognition Disorders
2
2010
559
0.050
Why?
Sex Distribution
1
2005
382
0.050
Why?
Anticoagulants
1
2009
746
0.050
Why?
Regression Analysis
2
2017
999
0.050
Why?
Hepatitis C, Chronic
1
2005
150
0.050
Why?
Practice Patterns, Physicians'
1
2013
1408
0.050
Why?
Erlotinib Hydrochloride
2
2014
71
0.050
Why?
Liver Cirrhosis
1
2005
278
0.050
Why?
Feasibility Studies
3
2011
1135
0.050
Why?
Propionates
1
2003
39
0.050
Why?
Drug-Related Side Effects and Adverse Reactions
1
2006
266
0.050
Why?
Chromatography, Affinity
3
1989
82
0.050
Why?
Preoperative Care
1
2005
396
0.050
Why?
Internship and Residency
1
2013
1281
0.050
Why?
Aniline Compounds
1
2003
120
0.050
Why?
Societies
1
2022
40
0.040
Why?
Clinical Trials, Phase III as Topic
2
2004
116
0.040
Why?
Pterygium
1
2000
4
0.040
Why?
Organizational Objectives
4
2001
67
0.040
Why?
Algorithms
2
2017
1849
0.040
Why?
Ontario
2
2017
91
0.040
Why?
Esophagoscopy
1
2002
223
0.040
Why?
Reproducibility of Results
2
2015
3416
0.040
Why?
Neurologic Examination
1
2000
129
0.040
Why?
Vincristine
2
2010
148
0.040
Why?
B7-H1 Antigen
1
2022
245
0.040
Why?
BRCA1 Protein
1
2020
84
0.040
Why?
Carcinoma, Bronchogenic
1
1999
20
0.040
Why?
Spinal Cord Neoplasms
1
1999
40
0.040
Why?
Receptors, Estrogen
2
2013
406
0.040
Why?
Carcinoma, Large Cell
1
1999
17
0.040
Why?
Neuropsychological Tests
3
2013
1149
0.040
Why?
Medical Records
2
2010
193
0.040
Why?
Liver Transplantation
1
2005
751
0.030
Why?
Reoperation
2
2012
645
0.030
Why?
Estrogens
1
2020
364
0.030
Why?
Urinary Bladder Neoplasms
1
2001
259
0.030
Why?
Iridium Radioisotopes
1
1997
4
0.030
Why?
Thoracic Vertebrae
1
2018
90
0.030
Why?
Epidemiologic Methods
1
2017
91
0.030
Why?
Aziridines
2
1994
6
0.030
Why?
Clinical Trials, Phase I as Topic
1
1997
49
0.030
Why?
Colorado
3
2014
4595
0.030
Why?
Skin Neoplasms
2
2017
806
0.030
Why?
Child, Preschool
7
2009
11913
0.030
Why?
Molecular Weight
2
1989
295
0.030
Why?
Biopsy, Needle
1
2017
183
0.030
Why?
Benzoquinones
2
1994
46
0.030
Why?
Esophagitis
2
2009
68
0.030
Why?
Respiration
1
2017
208
0.030
Why?
Memory Disorders
2
2010
198
0.030
Why?
Supratentorial Neoplasms
1
1996
18
0.030
Why?
Neutropenia
2
2009
153
0.030
Why?
Odds Ratio
1
1999
1077
0.030
Why?
Precision Medicine
1
2020
462
0.030
Why?
Heart
1
2020
626
0.030
Why?
Meningioma
1
1997
87
0.030
Why?
Propensity Score
1
2018
376
0.030
Why?
Sex Factors
2
2014
2107
0.030
Why?
Estrogen Receptor alpha
1
2017
154
0.030
Why?
Cerebral Angiography
1
1995
121
0.030
Why?
Forecasting
3
2001
388
0.030
Why?
Pilot Projects
3
2015
1888
0.030
Why?
Marital Status
1
2014
47
0.030
Why?
Technetium Tc 99m Pentetate
1
2014
7
0.030
Why?
Ventilation-Perfusion Ratio
1
2014
11
0.030
Why?
Nuclear Medicine
1
2014
9
0.030
Why?
Myocardium
1
2020
948
0.030
Why?
Vital Capacity
1
2015
293
0.030
Why?
Radioisotope Teletherapy
1
1993
2
0.030
Why?
Cobalt Radioisotopes
1
1993
7
0.030
Why?
Molecular Targeted Therapy
1
2017
447
0.030
Why?
Patient Safety
1
2017
352
0.020
Why?
Nervous System Diseases
1
1997
288
0.020
Why?
Texas
1
2014
280
0.020
Why?
Spatial Analysis
1
2013
20
0.020
Why?
Child
9
2009
22693
0.020
Why?
Vimentin
1
1993
47
0.020
Why?
SEER Program
1
2014
233
0.020
Why?
Developing Countries
1
2016
312
0.020
Why?
Radiodermatitis
1
1993
11
0.020
Why?
Prostatic Neoplasms
1
2001
972
0.020
Why?
Radiometry
1
2013
56
0.020
Why?
Monte Carlo Method
1
2013
151
0.020
Why?
Observer Variation
1
2014
356
0.020
Why?
Scalp
1
1993
38
0.020
Why?
Protein-Tyrosine Kinases
1
2016
429
0.020
Why?
Time
1
2013
85
0.020
Why?
Cerebral Cortex
1
1996
485
0.020
Why?
Mitosis
1
1993
195
0.020
Why?
Medical Errors
1
2013
124
0.020
Why?
Radiation Dosage
1
2013
193
0.020
Why?
Remission Induction
2
2008
308
0.020
Why?
Ascorbic Acid
1
1993
183
0.020
Why?
Radiology
1
2014
175
0.020
Why?
Disease Management
1
2016
651
0.020
Why?
International Agencies
1
2011
30
0.020
Why?
Diagnosis, Differential
1
2015
1503
0.020
Why?
Breast Neoplasms, Male
1
2011
29
0.020
Why?
Electrons
1
1991
82
0.020
Why?
Bronchography
1
2010
10
0.020
Why?
Fibrosis
1
2013
568
0.020
Why?
Sensitivity and Specificity
1
2015
1998
0.020
Why?
Infusions, Intravenous
2
2004
432
0.020
Why?
Procarbazine
1
1990
9
0.020
Why?
Lomustine
1
1990
18
0.020
Why?
Cell Nucleus
1
1993
584
0.020
Why?
Longitudinal Studies
1
2018
3017
0.020
Why?
Physics
1
2010
17
0.020
Why?
Selection Bias
1
2009
38
0.020
Why?
Clinical Trials Data Monitoring Committees
1
2009
3
0.020
Why?
Neoplasm, Residual
1
2010
143
0.020
Why?
Smoking
1
2017
1486
0.020
Why?
Hypophysectomy
1
1989
12
0.020
Why?
Quality Control
1
2010
163
0.020
Why?
Immunohistochemistry
1
1993
1712
0.020
Why?
Chromatin
1
1993
559
0.020
Why?
Platinum
1
2009
48
0.020
Why?
Incidence
1
2016
2936
0.020
Why?
Adrenal Cortex
1
1989
33
0.020
Why?
Prevalence
1
2016
2861
0.020
Why?
Hepatic Veno-Occlusive Disease
1
2008
12
0.020
Why?
Bronchi
1
2010
263
0.020
Why?
Neoplasms, Unknown Primary
1
1988
20
0.020
Why?
Prostheses and Implants
1
2010
137
0.020
Why?
Liver Regeneration
1
2008
41
0.020
Why?
Certification
1
2010
118
0.020
Why?
beta-Lipotropin
2
1985
2
0.020
Why?
Endorphins
2
1985
9
0.020
Why?
Polymorphism, Single Nucleotide
1
2016
2240
0.020
Why?
Anti-Inflammatory Agents
1
2012
474
0.020
Why?
Epinephrine
1
1989
160
0.020
Why?
Motion
1
2008
94
0.020
Why?
Fracture Fixation, Intramedullary
1
1988
61
0.020
Why?
International Cooperation
1
2008
193
0.020
Why?
Administration, Oral
1
2010
872
0.020
Why?
Mental Status Schedule
1
2007
34
0.020
Why?
Reference Values
1
1989
796
0.020
Why?
Infant
4
1999
10114
0.020
Why?
Creatinine
1
1989
511
0.020
Why?
Bleomycin
1
2009
255
0.020
Why?
Genetic Predisposition to Disease
1
2016
2488
0.020
Why?
Rectal Neoplasms
1
2008
160
0.020
Why?
Predictive Value of Tests
2
2008
2113
0.020
Why?
Chromatography, High Pressure Liquid
1
1989
588
0.020
Why?
Southwestern United States
1
2006
93
0.020
Why?
Neovascularization, Pathologic
1
2008
287
0.010
Why?
California
1
2008
475
0.010
Why?
Chromium Compounds
1
2006
2
0.010
Why?
Glucocorticoids
1
2010
536
0.010
Why?
Pleural Effusion, Malignant
1
2006
12
0.010
Why?
Polycythemia Vera
1
2006
9
0.010
Why?
Sodium Iodide
1
2006
4
0.010
Why?
Hydrocephalus
1
1987
115
0.010
Why?
Hyperthyroidism
1
2006
22
0.010
Why?
Patient Isolation
1
2006
20
0.010
Why?
Ascites
1
2006
48
0.010
Why?
Yttrium Radioisotopes
1
2006
64
0.010
Why?
DNA Repair
1
2008
255
0.010
Why?
Methadone
1
1987
130
0.010
Why?
DNA Damage
1
2008
439
0.010
Why?
Chromatography
1
1985
27
0.010
Why?
Concanavalin A
1
1985
72
0.010
Why?
Organophosphorus Compounds
1
2006
84
0.010
Why?
Phosphates
1
2006
175
0.010
Why?
ACTH Syndrome, Ectopic
1
1984
1
0.010
Why?
Organometallic Compounds
1
2006
110
0.010
Why?
Occipital Lobe
1
2004
30
0.010
Why?
Lymphoma, Non-Hodgkin
1
2006
124
0.010
Why?
Biotransformation
1
1984
61
0.010
Why?
Patient Education as Topic
1
2010
770
0.010
Why?
Carbohydrate Metabolism
1
1984
59
0.010
Why?
Brain Edema
1
2004
63
0.010
Why?
Thrombocytopenia
1
2006
206
0.010
Why?
Arginine Vasopressin
1
1984
44
0.010
Why?
Recurrence
2
2000
1133
0.010
Why?
Genomics
1
2009
853
0.010
Why?
Vomiting
1
2004
131
0.010
Why?
Corticotropin-Releasing Hormone
1
1984
72
0.010
Why?
Oils
1
1983
22
0.010
Why?
Motor Skills
1
2004
103
0.010
Why?
Bipolar Disorder
1
1985
285
0.010
Why?
Thyroid Neoplasms
1
2006
380
0.010
Why?
Immunologic Factors
1
2003
244
0.010
Why?
Antimetabolites, Antineoplastic
1
2001
108
0.010
Why?
Pain
1
2006
790
0.010
Why?
Psychometrics
1
2004
712
0.010
Why?
Postoperative Period
1
2000
355
0.010
Why?
Apoptosis
1
2008
2439
0.010
Why?
Thorax
1
1999
51
0.010
Why?
Michigan
1
1999
203
0.010
Why?
Opioid-Related Disorders
1
1987
634
0.010
Why?
Cysts
1
1999
108
0.010
Why?
Bias
1
1999
197
0.010
Why?
Antibodies, Monoclonal
1
2006
1512
0.010
Why?
Mercaptopurine
1
1996
15
0.010
Why?
Mitomycin
1
1996
31
0.010
Why?
Meninges
1
1997
54
0.010
Why?
Biopsy
1
1999
1075
0.010
Why?
Cross-Sectional Studies
1
2007
5899
0.010
Why?
Autoantibodies
1
1983
1500
0.010
Why?
Cause of Death
1
1996
456
0.010
Why?
Decision Making
1
2001
993
0.010
Why?
Solutions
1
1993
160
0.010
Why?
Neoplasms, Radiation-Induced
1
1993
100
0.010
Why?
Cerebral Hemorrhage
1
1993
125
0.010
Why?
Computer Simulation
1
1995
1014
0.010
Why?
Patient Compliance
1
1994
589
0.000
Why?
Evaluation Studies as Topic
1
1989
161
0.000
Why?
Double-Blind Method
1
1993
2070
0.000
Why?
Melanocyte-Stimulating Hormones
1
1985
3
0.000
Why?
Lithium
1
1985
38
0.000
Why?
Postoperative Complications
1
1996
3034
0.000
Why?
Brassica
1
1983
5
0.000
Why?
Spain
1
1983
50
0.000
Why?
Drug Synergism
1
1984
354
0.000
Why?
Antigen-Antibody Complex
1
1983
70
0.000
Why?
In Vitro Techniques
1
1984
1041
0.000
Why?
Syndrome
1
1983
380
0.000
Why?
Sheep
1
1984
870
0.000
Why?
Animals
1
1984
38107
0.000
Why?
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)